Get the Stockscreener App
0.9079
3.41%
-0.0321
After Hours:
.91
0.0021
+0.23%
Cytosorbents Corp stock is traded at $0.9079, with a volume of 96,721.
It is down -3.41% in the last 24 hours and down -6.40% over the past month.
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.
See More
Previous Close:
$0.94
Open:
$0.93
24h Volume:
96,721
Relative Volume:
0.81
Market Cap:
$68.25M
Revenue:
$33.79M
Net Income/Loss:
$-18.67M
P/E Ratio:
-2.5346
EPS:
-0.3582
Net Cash Flow:
$-19.17M
1W Performance:
-16.71%
1M Performance:
-6.40%
6M Performance:
+5.30%
1Y Performance:
+3.17%
1-Day Range:
$0.8999
$0.93
1-Week Range:
$0.87
$1.12
52-Week Range:
$0.70
$1.61
Cytosorbents Corp Stock (CTSO) Company Profile
Name
Cytosorbents Corp
Sector
Industry
Phone
973-329-8885
Address
305 COLLEGE ROAD EAST, PRINCETON, NJ
Compare CTSO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CTSO
Cytosorbents Corp
|
0.9079 | 68.25M | 33.79M | -18.67M | -19.17M | -0.3582 |
|
ABT
Abbott Laboratories
|
132.60 | 224.65B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
104.24 | 151.13B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
381.36 | 139.34B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
83.45 | 107.01B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
75.11 | 44.25B | 5.54B | 4.18B | 259.90M | 7.00 |
Cytosorbents Corp Stock (CTSO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-07-23 | Initiated | B. Riley Securities | Buy |
| Oct-14-21 | Resumed | B. Riley Securities | Buy |
| Sep-17-20 | Initiated | Jefferies | Buy |
| Sep-01-20 | Initiated | SVB Leerink | Outperform |
| Aug-08-17 | Reiterated | Maxim Group | Buy |
| Oct-26-16 | Initiated | Aegis Capital | Buy |
| May-24-16 | Initiated | Maxim Group | Buy |
| Oct-29-15 | Upgrade | WBB Securities | Speculative Buy → Buy |
| May-12-15 | Reiterated | MLV & Co | Buy |
| Apr-01-15 | Reiterated | MLV & Co | Buy |
| Mar-05-15 | Initiated | MLV & Co | Buy |
| Feb-25-15 | Initiated | WBB Securities | Speculative Buy |
| Jan-27-15 | Reiterated | H.C. Wainwright | Buy |
View All
Cytosorbents Corp Stock (CTSO) Latest News
Cytosorbents’ (CTSO) “Buy” Rating Reiterated at D. Boral Capital - Defense World
Behind Cytosorbents Corp’s 52-Week Range: Uncovering Opportunities for Investors - investchronicle.com
Today’s watch list includes Cytosorbents Corp (NASDAQ:CTSO) stock - uspostnews.com
CytoSorbents (CTSO) Stock: Analyst Maintains "Buy" Rating with $ - GuruFocus
Demystifying CytoSorbents: Insights From 4 Analyst Reviews - Benzinga
FDA denies CytoSorbents’ request for DrugSorb-ATR device - Investing.com
CytoSorbents: FDA issues denial letter for De Novo Request for DrugSorb-ATR - TipRanks
CytoSorbents (CTSO) Awaits FDA Approval for Breakthrough Device DrugSorb-ATR | CTSO Stock News - GuruFocus
CytoSorbents Provides Regulatory Update for DrugSorb-ATR - PR Newswire
Cytosorbents (NASDAQ:CTSO) versus Microbot Medical (NASDAQ:MBOT) Financial Analysis - Defense World
CytoSorbents to Report First Quarter 2025 Financial Results and Recent Business Highlights - Longview News-Journal
CytoSorbents, Blood Purification Leader, Reveals Q1 2025 Results and Business Updates May 14 - Stock Titan
StockNews.com Initiates Coverage on Cytosorbents (NASDAQ:CTSO) - Defense World
CytoSorbents secures $1.7M via NJ tax credit transfer - Investing.com
CytoSorbents Lands $1.7M Strategic Funding: New DrugSorb Product Launch and Manufacturing Expansion Ahead - Stock Titan
Cytosorbents (NASDAQ:CTSO) Now Covered by StockNews.com - Defense World
CytoSorbents Appoints Melanie Grossman, CPA as Vice President and Corporate Controller - PR Newswire
Cytosorbents Appoints Thomas Shannon As Vice President Of Marketing For North America - marketscreener.com
CytoSorbents Appoints Thomas Shannon as Vice President of Marketing for North America - PR Newswire
Strategic Hire: Medtronic $450M Portfolio Leader Joins CytoSorbents to Drive Breakthrough Device Launch - Stock Titan
Raymond James Financial Inc. Takes Position in Cytosorbents Co. (NASDAQ:CTSO) - Defense World
Cytosorbents (NASDAQ:CTSO) Now Covered by Analysts at StockNews.com - Defense World
Analysts Offer Predictions for Cytosorbents Q1 Earnings - Defense World
Brokers Offer Predictions for Cytosorbents Q1 Earnings - Defense World
Analysts Set Expectations for Cytosorbents FY2028 Earnings - Defense World
Cytosorbents (NASDAQ:CTSO) Earns “Neutral” Rating from HC Wainwright - Defense World
CytoSorbents extends Series B Warrants expiration to June 10 - Investing.com
Cytosorbents CorpExtends Expiration Date Of Series B Right Warrants To June 10, 2025SEC Filing - MarketScreener
CytoSorbents extends Series B Warrants expiration to June 10 By Investing.com - Investing.com UK
CytoSorbents Gives Investors More Time: Series B Warrants Now Extended to June 2025 - Stock Titan
Cytosorbents (NASDAQ:CTSO) Coverage Initiated at StockNews.com - Defense World
Cytosorbents (NASDAQ:CTSO) Given Buy Rating at D. Boral Capital - Defense World
Cytosorbents Corp Reports Strong Growth Amid Challenges - TipRanks
CytoSorbents Corp Q4 2024 Earnings: EPS Misses at -$0.06, Revenue Falls Short at $9.2 Million - GuruFocus
The Analyst Verdict: CytoSorbents In The Eyes Of 4 Experts - Benzinga
Cytosorbents Corporation (NASDAQ:CTSO) Q4 2024 Earnings Call Transcript - Insider Monkey
CytoSorbents: Q4 Earnings Snapshot - CT Insider
CytoSorbents Corp (CTSO) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ... - Yahoo Finance
Cytosorbents (CTSO) Sees Significant Growth in Q4 and 2024 Reven - GuruFocus
CytoSorbents Corp (CTSO) Q4 2024 Earnings Call Highlights: Stron - GuruFocus
CytoSorbents Corporation Reports Strong 2024 Performance - TipRanks
Earnings call transcript: Cytosorbents Crp Q4 2024 beats EPS forecast By Investing.com - Investing.com Canada
CTSOCytosorbents Corp Latest Stock News & Market Updates - Stock Titan
Cytosorbents Corp reports results for the quarter ended December 31Earnings Summary - TradingView
Cytosorbents Corp SEC 10-K Report - TradingView
CytoSorbents Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights - TradingView
CYTOSORBENTS Earnings Results: $CTSO Reports Quarterly Earnings - Nasdaq
Cytosorbents (CTSO) Expected to Post Improved Earnings and Reven - GuruFocus
Insights into CytoSorbents's Upcoming Earnings - Benzinga
CytoSorbents Corp (CTSO) Q4 2024 Earnings Report Preview: What t - GuruFocus.com
Cytosorbents (CTSO) Expected to Announce Quarterly Earnings on Monday - Defense World
Cytosorbents Corp Stock (CTSO) Financials Data
Revenue
Net Income
Cash Flow
EPS
11.62%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):